Abstract: The present invention relates to a medical device for placement at a predetermined location within a passageway of the human body, and more particularly, relates to a flexible embolization device which may be delivered by a catheter to a pre-selected position within a blood vessel to thereby embolize a blood vessel or a blood vessel defect, such as an aneurysm or fistula. Specifically, the embolization device comprises an elongated coil having a lumen, the coil and lumen being at least partially embedded in an elongated foam member comprising, in some embodiments, a flexible, biodegradable, water insoluble, open, interconnecting-cell foam material having embolic characteristics, and capable of allowing cell proliferation into the open cell foam interior.

Abstract: A stretch-resistant occlusive device having an elongated, substantially cylindrical porous elastomeric structure and at least one of an elongated stretch-resistant tube and at least one stretch-resistant filament. The porous structure lies within an elongated outer embolic structure such as a helically wound embolic coil.

Abstract: An occlusive device suitable for endovascular treatment of an aneurysm in a region of a parent vessel in a patient, including a structure having a fixed porosity and having dimensions suitable for insertion into vasculature of the patient to reach the region of the aneurysm in the parent vessel. The device further includes a frangible material supported by the structure which initially provides a substantial barrier to flow through the frangible material and is capable of at least one of localized rupturing and localized eroding, in the presence of a pressure differential arising at an ostium of a perforator vessel communicating with the parent vessel, within an acute time period to minimize ischemia downstream of the perforator vessel.

Abstract: The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type I (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration.

Abstract: A stretch-resistant occlusive device, and method of manufacturing such a device, having a helically wound coil defining a coil lumen extending along the entire axial length of the coil from a proximal end portion to a distal end portion. The device further includes a headpiece having a proximal end, a distal end attached to the proximal end portion of the coil, and a headpiece lumen extending between the proximal and distal ends of the headpiece. An anchor filament extends through the headpiece lumen, has at least one proximal end secured to the proximal end of the headpiece, and has a distal portion defining an eye positioned distal to the distal end of the headpiece. A stretch resistant member is positioned within the coil lumen, has a proximal portion extending through the eye, and has at least one distal end secured to the distal end of the coil.

Abstract: The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo[2.2.

Abstract: Quinuclidine derivative of the general formula (I) in the form of single enantiomers or mixtures thereof are useful in the manufacture of a medicament for the prevention and therapy of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cough and emphysema wherein: R1 is selected from H, F, Cl, Br, I and (C1-C4)-alkyl; R2 is optionally substituted 2- or 3-thienyl, or substituted phenyl; R3 is (CH2)1-4—COR4 or (CH2)1-4—S(O)nR4, wherein R4 is optionally substituted phenyl or optionally substituted 2- or 3-thienyl; n is 0, 1 or 2; X? is a pharmaceutically acceptable anion.

Abstract: Compounds of formula (I), and their pharmaceutically acceptable salts and solvates, wherein X represents —O—, —NH—, —S—, —NHC(?O)— or —NHC(?S)—; R1 represents —H or a hydrocarbon chain; R2 represents —H, alkoxy, amino, a hydrocarbon chain or a radical of a cycle; R3 represents —H, a hydrocarbon chain or a radical of a cycle; R4 represents —H or a hydrocarbon chain; alternatively R3 and R4 form together a cycle; R5 and R6 represent —H or halogen, and R7 represents —H, a hydrocarbon chain or heteroaryl, are useful against bacterial infections in animals, including humans.

Abstract: A handle for use with an implantable medical device deployment system that guides and deploys the medical device at a target location within a body vessel. The handle includes a rotatable member, rotation of which causes movement of a control member of the deployment system in an axial direction. An actuator in a handle may include a threaded portion which has at least two different pitch sizes.

Abstract: A detachment actuator for use with an implantable medical device deployment system that guide and deploys the medical device at a target location within a body vessel. The detachment actuator includes a first portion that is connected the implantable medical device and a second portion that is attached to a control member the controls the release of the medical device, The second portion of the detachment actuator detaches and moves away from the first portion of the detachment actuator to move the control member and release the medical device.

Abstract: An actuator handle for use with an implantable medical device deployment system. The actuator handle includes a first actuator and a second actuator for manipulating and controlling first and second retaining members of the deployment system to effectuate release of a medical device from the deployment system.

Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)-B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed herein. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.

Abstract: Carbamate of general formula (I), wherein R1, R2, and R3 are H, OH, NO2, SH, CN, F, Cl, Br, I, COOH, CONH2, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylsulfanyl, (C1-C4)-alkylsulfinyl, (C1-C4)-alkylsulfonyl, (C1-C4)-alkoxyl optionally substituted with one or several F, and (C1-C4)-alkyl optionally substituted with one or several F or OH; R4 is cycloalkyl, phenyl, heteroaryl or a bicyclic ring system; R5 is cycloalkyl, (C5-C10)-alkyl, a substituted (C1-C10)-alkyl; and X? is a physiologically acceptable anion. Carbamate (I) is selective M3 receptor antagonists versus M2 receptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions.

Abstract: Radiopaque markers for use with stents implantable within a body vessel are provided with one or more through-holes. Each through-hole extends through the thickness of the marker to expose a portion of the stent underlying the marker. The marker is welded to the stent through each through-hole. Also provided are stents incorporating a radiopaque marker having one or more through-holes suitable for receiving a weld. Methods are provided for securing a radiopaque marker having one or more through-holes to a stent.

Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)—B-J-T; and s. R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.

Abstract: A polymeric coating is applied to at least one embolic coil carried in a fixture, at least a portion of said embolic coil being generally vertical and straight. The coil is carried in the fixture during the processing, and may remain in the fixture if desired for further steps of processing.

Abstract: A medical device for placing an embolic device at a predetermined site within a vessel of the body including a delivery catheter and a flexible pusher member having a lumen therethrough and being slidably disposed within the lumen of the catheter. An embolic device is retained within the delivery catheter by a mechanical interlocking mechanism which includes an engagement member which is attached to the distal end of the pusher member and extends through a retaining ring at the proximal end of the embolic device. A detachment member extends through an aperture at the distal end of the engagement member thereby locking the embolic device onto the pusher member. When the embolic device is advanced to the predetermined site within the vessel, the detachment member is withdrawn from the aperture to thereby release the embolic device at the treatment site.

Abstract: A medical device for placing an embolic device at a predetermined site within a vessel of the body including a delivery catheter and a flexible pusher member having a lumen therethrough and being slidably disposed within the lumen of the catheter. A stretch resistant embolic device is retained within the delivery catheter by a mechanical interlocking mechanism which includes an engagement member which is attached to the distal end of the pusher member and extends through a retaining ring at the proximal end of the embolic device. A detachment member extends through an aperture at the distal end of the engagement member thereby locking the embolic device onto the pusher member. The engagement member engages a retaining ring on the embolic device. When the embolic device is advanced to the predetermined site within the vessel, the detachment member is withdrawn from the aperture to thereby release the embolic device at the treatment site.

Abstract: Thin film metallic devices implantable within a human subject for occlusion of an aneurysm or blood vessel are provided. The devices are movable from a porous, elongated, collapsed configuration for delivery to a deployed configuration within the body. The pores telescope as the device moves to its deployed configuration, which causes the device to longitudinally foreshorten and radially expand, while also decreasing in porosity for preventing blood flow. The occlusion devices may be either self-supporting or supported by a strut structure. Additionally, the occlusion devices may comprise a plurality of layers having unaligned pore systems which further reduce porosity in the deployed configuration.

Abstract: A vascular occlusion device deployment system for deploying an occlusion device at a preselected site within the vasculature of a patient. The deployment system includes a pusher which has a constrictor located at the distal end portion of the pusher. The constrictor has a channel which receives a portion of the occlusion device. The constrictor has a proximal end portion and a distal end portion wherein the proximal end portion can be moved relative to the distal end portion to reduce the size of the channel. When the channel size is reduced, the constrictor grasps the portion of the occlusion device located within the channel. When it is desired to deploy the coil, the constrictor is moved in the opposite direction to increase the size of the channel and release the coil's grasp of the occlusion device.